NCOA3 and cancer: This suggests, that except for the known mutually compensatory roles that nuclear co-activators have, adoption of an alternative survival mechanism by a cancer cell during pharmacological pressure might not only make the drug target redundant but in cases of a pleiotropic target such as SRC-3, its loss might be favorable for cancer cell proliferation under a distinct and newly adapted biological state.